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Abstract We found that the sequences YPLDL and YPLDLF
in the large subunit of spinach D-ribulose-1,5-bisphosphate
carboxylase/oxygenase (Rubisco) met the structure YP-aliphatic
amino acid which might have opioid activity. We then synthesized
these peptides to test their opioid activity. The IC50 of these
peptides in mouse vas deferens assay were 51.0 WM and 24.4 WM,
respectively, and those in N receptor binding assay using
[3H]deltorphin II as radioligand were 2.09 WM and 0.93 WM,
respectively. Both peptides were selective for N receptor. We
named them rubiscolin-5 and -6, respectively. Rubiscolin-5 and -6
have antinociceptive activity in mice after i.c.v. or oral
administration. The enzymatic conditions to release rubiscolin
were investigated using both spinach Rubisco and synthetic
fragment peptides. This is the first example of bioactive peptides
derived from plant Rubisco. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Rubisco, (D-ribulose-1,5-bisphosphate carboxylase/oxygen-
ase; EC 4.1.1.39), is the key enzyme for carbon dioxide ¢x-
ation and photorespiration. This enzyme is responsible for
food production for the entire biosphere. Because of its abun-
dance (about 30^50% of soluble protein in green leaves of
plants), the enzyme itself serves as food. Many kinds of bio-
active peptides have been isolated from enzymatic digests of
food proteins. In this study, we investigated whether any bio-
active peptides are derived from Rubisco.
It was well established that opioid peptides containing YPX
sequence in these molecules usually have aromatic amino
acids X; for example, X is Phe in L-casomorphin and endo-
morphin-2, while in hemorphin and endomorphin-1, X is Trp
[1^3]. However, accumulating evidence indicates that aliphatic
amino acids X in YPX sequence also contribute to onset of
opioid activity, as in the case of gluten exorphin A5 (GYYPT)
[4], gluten exorphin C (YPISL) [5], Tyr-MIF-1 [6], and neo-
casomorphin (YPVEPF) [7]. Given all this, we hypothesize
that aliphatic X in addition to aromatic ones, can also induce
opioid activity. To sustain this hypothesis, we searched for
the relevant sequence in spinach Rubisco large subunit and
noticed that sequences YPLDL (residues 103^107) and
YPLDLF (residues 103^108) would meet the above-men-
tioned requirement. To scrutinize their properties in detail,
we synthesized these peptides, and investigated their opioid
nature as well as the condition leading to their release by
intestinal enzymatic digestions.
2. Materials and methods
2.1. Chemicals and reagents
Fmoc-amino acids and Alko resins were from Watanabe Chemicals
Co. Ltd, Japan. Naltrindole was from RBI (Natick, MA, USA).
[3H][D-Ala2, MePhe4, Glycol5]enkephalin (DAMGO), [3H]deltorphin
II (Delt II) and [3H][D-Pen2, D-Pen5]enkephalin (DPDPE) were from
NEN (Boston, MA, USA). Spinach Rubisco, pepsin, chymotrypsin,
leucine aminopeptidase (LAP) and protease inhibitor cocktail (prod-
uct number P8340) were from Sigma. Elastase and naloxone hydro-
chloride were from Wakenyaku Co., Ltd, Japan.
2.2. Animals
Male Hartley guinea pigs for guinea pig ileum (GPI) assay, male
Wistar rats for brain membrane preparation, retired male ICR mice
for mouse vas deferens (MVD) assay, and male ddy mice for anti-
nociceptive test were purchased from Shimizu Experimental Animals
(Kyoto, Japan). They were housed for at least 2 days under standard
conditions (23 þ 1‡C, 55 þ 5% humidity, light^dark cycle with light
on between 7.00 and 19.00 h) with free access to food and water.
All procedures in this study were performed in accordance with the
guidelines for the care and use of laboratory animals of Kyoto Uni-
versity.
2.3. Peptide synthesis and puri¢cation
Peptides (YPLDL, YPLDLF and ICYVAYPLDLFEEG corre-
sponding to residues 98^111 of spinach Rubisco large subunit) were
synthesized on PS3 peptide synthesizer (Protein Technologies) by
Fmoc strategy. Synthetic peptides were puri¢ed by HPLC on an oc-
tadecyl silica (ODS) column (Cosmosil 5C18-AR, 20U250 mm, Na-
calai Tesque). The synthetic peptide fragment for enzymatic hydroly-
sis was further puri¢ed on a phenethyl silica column (Cosmosil 5PE-
MS, 10U250 mm, Nacalai Tesque). The column was developed with a
linear gradient of acetonitrile (0^40%/40 min) containing 0.1% TFA at
£ow rates of 10 ml/min for ODS column and 3 ml/min for phenethyl
silica column.
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2.4. Opioid activity assays
Opioid activity was measured by MVD assay and GPI assay as
described previously [4]. Antinociceptive e¡ect was tested in mice by
tail pinch method according to [8].
2.5. Radioreceptor assay
Receptor binding assay was accomplished essentially as described
[4]. For W receptor binding assay, rat brain membrane was used at a
¢nal protein concentration of 1 mg/ml with 1 nM [3H]DAMGO as
radioligand. For N receptor binding assay, one set of experiment was
done with rat brain membrane using 1 nM N2 agonist [3H]Delt II as
radioligand, and another set with membrane (¢nal protein concentra-
tion 60 Wg/ml) made from CHO cells stably expressing human N
opioid receptor using 1 nM N1 agonist [3H]DPDPE as radioligand.
The transfected CHO cell was cultured and membrane was prepared
as described [9]. Non-speci¢c binding was determined in the presence
of 10 WM naloxone. All assays were performed in the presence of
protease inhibitor cocktail containing 4-(2-aminoethyl)-benzenesulfo-
nyl £uoride (AEBSF) 1 mM, aprotinin 0.8 WM, leupeptin 22 WM,
bestatin 40 WM, pepstatin A 15 WM, and E-64 14 WM. The IC50 value
is the concentration that inhibits the binding of radioligands by 50%.
2.6. Enzymatic digestion of spinach Rubisco and synthetic peptide
fragment
50 mg of spinach Rubisco at a concentration of 10 mg/ml was
digested by pepsin (E/S = 1/50, w/w) for 4 h at 37‡C. The reaction
was stopped by adjusting the pH to 8.0 with 1 N NaOH. Then,
half of the digest was further hydrolyzed by LAP for 8 h at 37‡C
(E/S = 1/50, w/w), and the hydrolysis was stopped by boiling. The
digests of spinach Rubisco were fractionated by HPLC on an ODS
column (Cosmosil 5C18-AR, 20U250 mm, Nacalai Tesque) with a
linear gradient of acetonitrile (0^50%/50 min) containing 0.1% TFA
at a £ow rate of 10 ml/min, and dried with a centrifugal concentrator.
Potential fractions judged by their retention time relative to those of
standard YPLDLF and YPLDL were further puri¢ed on a phenethyl
silica column (Cosmosil 5PE-MS, 4.6U250 mm, Nacalai Tesque) with
a linear gradient of acetonitrile (0^50%/50 min) containing 0.1% TFA
at £ow rate of 1 ml/min. The potential fractions were further puri¢ed
on a cyanopropyl silica column (Cosmosil 5CN-R, 4.6U250 mm,
Nacalai Tesque), dried on centrifugal concentrator and analyzed by
Protein Sequencer (Type 492, Applied Biosystems), or con¢rmed by
liquid chromatography coupled with mass spectrography (LC-Mass,
Mariner, Applied Biosystems). The peptide ICYVAYPLDLFEEG
corresponding to the residues 98^111 in the large subunit of spinach
Rubisco was digested at a concentration of 2 mg/ml (200 Wl/experi-
ment) with pepsin, elastase and chymotrypsin (E/S = 1/20, w/w) for 2 h
at 37‡C. Half of the digests was further digested by LAP (E/S = 1/20,
w/w) for 1 h at 37‡C. The pepsin digest was neutralized by NaOH.
Finally, the reactions were stopped by boiling. The digests of synthetic
peptide fragment were applied onto LC-Mass directly. The yields of
individual peptides were calculated by the area of absorbance at 280
nm in HPLC or LC-Mass charts.
2.7. Data analyses
Data from GPI assay, MVD assay, receptor binding assay, and
antinociceptive test were expressed as means þ S.E.M. Comparisons
between two groups were carried out by Student’s t-test. For all sta-
tistical analyses, the di¡erences were considered signi¢cant at
P6 0.05.
3. Results
3.1. Opioid activities of synthetic YPLDL and YPLDLF
To test whether the sequences YPLDL and YPLDLF have
opioid activity, we synthesized them and applied them to in
vitro biological assays. In MVD assay, YPLDL and YPLDLF
exhibited typical suppressive activity on ¢eld-stimulated con-
traction (Fig. 1). Naloxone reversed their e¡ects, indicating
opioid activity of these peptides. The IC50 of YPLDL and
YPLDLF in MVD assay were 51.0 WM and 24.4 WM, respec-
tively, while those in GPI assay were 1110 WM and 748 WM,
respectively. Accordingly, both peptides are characterized as N
selective opioid agonists. The selectivity toward N against W in
terms of IC50 ratio in GPI and MVD assays were 21.8 for
YPLDL and 30.7 for YPLDLF. In N receptor binding assay,
YPLDL showed IC50 of 1.97 WM in replacing [3H]DPDPE
and 2.09 WM in replacing [3H]Delt II, with the IC50 of
YPLDLF being 0.90 WM and 0.93 WM, respectively (Table
1). There is not much di¡erence in their N receptor a⁄nity
irrespective of N1 ([3H]DPDPE) or N2 ([3H]Delt II) agonist
being used as radioligand. The IC50 of YPLDL in W receptor
binding assay using [3H]DAMGO as radioligand was 1085
WM, and that for YPLDLF was more than 2000 WM. In ac-
cordance with the results from MVD and GPI assay, both
Fig. 1. Typical suppressive e¡ect of rubiscolin-5 and -6 on ¢eld-stimulated contraction in MVD assay.
Table 1
Opioid activities and receptor a⁄nities of rubiscolin-5 and -6
Peptides Opioid activities IC50 (WM) GPI/MVB Receptor a⁄nities IC50 (WM)
GPI MVD [3H]DAMGO [3H]Delt II [3H]DPDPE
YPLDL (rubiscolin-5) 1110 þ 71 51.0 þ 6.6 21.8 1085 þ 165 2.09 þ 0.06 1.97 þ 0.30
YPLDLF (rubiscolin-6) 748 þ 207 24.4 þ 3.6 30.7 s 2000 0.93 þ 0.04 0.90 þ 0.29
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peptides were found rather weak as W agonists. The homology
of Rubisco large subunits is relatively high among many spe-
cies, besides the sequence YPLDLF being preserved in most
plant species. Now that properties of both peptides are char-
acterized, we named them rubiscolin-5 and rubiscolin-6, re-
spectively.
3.2. The antinociceptive e¡ect of rubiscolin-5 and rubiscolin-6
After demonstrating the N opioid activity of rubiscolin-5
and -6 in in vitro bioassays, we proceeded to investigate
their e¡ects in vivo by determining their antinociceptive
e¡ects in mice using the tail pinch method. Rubiscolin-5
and rubiscolin-6 gave signi¢cant antinociceptive e¡ect after
i.c.v. administration at minimum doses of 3 nmol/mouse
and 1 nmol/mouse, respectively. Fig. 2A shows the represen-
tative time course of the antinociceptive e¡ect of rubiscolin-6,
which lasts for nearly 30 min. The dose response is given in
Fig. 2B after calculating the area under curve (AUC) in the
time course graph. Both peptides also exhibited antinocicep-
tive e¡ect after oral administration at higher doses (Fig. 2C).
The results indicate that rubiscolin-6 is nearly three times
more potent than rubiscolin-5. The antinociceptive e¡ect was
mediated by N opioid receptor because a selective N opioid
antagonist naltrindole blocked antinociception induced by
rubiscolin-6 (Fig. 2D).
3.3. Enzymatic release of rubiscolins from spinach Rubisco and
synthetic precursor
After con¢rming their typical N opioid activities, we then
investigated whether rubiscolin-5 and -6 could be released
from Rubisco by gastrointestinal enzymatic digestion. Our
results evidenced that rubiscolin-5 could be released from spi-
nach Rubisco after pepsin digestion with a yield of 0.17% mol
per mol Rubisco large subunit. Subsequent LAP digestion of
the pepsin digest of spinach Rubisco improved the yield of
rubiscolin-5 to 5.0% (Table 2). Under the same condition,
rubiscolin-6 was not detected. Digestion of synthetic peptide
fragment ICYVAYPLDLFEEG might allow a better under-
standing of the sites and extent of enzymatic cleavage. There-
fore, we synthesized this fragment, which corresponds to res-
idues 98^111 of spinach Rubisco large subunit. Pepsin
digestion of this peptide fragment can release both YPLDL
and YPLDLF with the yield of 0.30% and 0.04%, respectively.
The predominant product by pepsin digestion is VAYPLDL,
suggesting that the peptide bond between Tyr100 and Val 101,
and that between Leu107 and Phe108 are readily cleaved by
pepsin (Fig. 3).
Coupled with the ¢nding that trace amounts of
VAYPLDLF and YPLDLF were also released, it is conceiv-
able that pepsin can also cleave the peptide bond between
Ala102 and Tyr103, and that between Phe108 and Glu109
(Fig. 3). Subsequent LAP digestion greatly improved the
yield of YPLDL up to 40% (Table 2), presumably as a result
of LAP-induced removal of Val and Ala from VAYPLDL,
albeit no cleavage of Y-P bond. However, the yield of
YPLDLF was slightly decreased. It is possible that some other
contaminating enzyme in LAP might be responsible for this
decrease, because it can not be explained by the speci¢city
of LAP as described above. The enzymatic cleavage sites
for pepsin and LAP are given in Fig. 3. We also hydrolyzed
the synthetic fragment by pancreatic elastase and chymotryp-
sin. Nevertheless, neither YPLDL/YPLDLF nor amino-/car-
Fig. 2. Antinociceptive e¡ects of rubiscolin-5 and -6 in tail pinch
test in mice. A: Time course of rubiscolin-6 after i.c.v. administra-
tion. B: Dose response of rubiscolin-5 and -6 after i.c.v. administra-
tion. C: Dose response of rubiscolin-5 and -6 after p.o. administra-
tion. D: E¡ect of N opioid antagonist naltrindole (NTI, 1 mg/kg,
s.c.) on the antinociceptive e¡ect of rubiscolin-6 (35 nmol/mouse,
i.c.v.). NTI was given 10 min before rubiscolin-6 administration
(i.c.v.). In B, C and D, the AUC of response latency versus time
was calculated for each mouse. Results are expressed as mean þ
S.E.M., with n = 5 or 6 for each group. *P6 0.05, **P6 0.01,
***P6 0.001 versus saline control. ##P6 0.01 versus saline (s.c) fol-
lowed by rubiscolin-6 (i.c.v.).
Table 2
Enzymatic release of rubiscolin-5 and -6 from spinach Rubisco or
from peptide fragment corresponding to spinach Rubisco large sub-
unit (98^111)
Substrate(s) Enzyme(s) Peptide yield
(mol%)
YPLDL YPLDLF
Spinach Rubisco Pepsin 4 h 0.17 ND
Pepsin 4 h, LAP 8 h 5.0 ND
ICYVAYPLDLFEEG Pepsin 2 h 0.30 0.04
Pepsin 2 h, LAP 1 h 40 0.02
The yields from spinach Rubisco were expressed as (mol peptide/
mol large subunit, %). ND means not detected.
Fig. 3. Cleavage sites in spinach Rubisco large subunit by gastroin-
testinal proteases leading to the release of rubiscolin-5 and rubisco-
lin-6. Solid arrows indicate main sites, while dashed arrows indicate
minor sites.
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boxyl-terminally elongated ones were detected (data not
shown).
4. Discussion
From the digests of food proteins, many bioactive peptides
have been isolated, such as opioid and opioid antagonist
peptides [1,3^5,7,10^18], vasorelaxing or vasoconstricting
peptides [19,20], inhibitory peptides of angiotensin-convert-
ing enzyme [21^23] and immunostimulating peptides [24^26].
Because of the abundance of Rubisco in plant green leaves
including some vegetables, Rubisco should be a protein
source not only for animals but also for human being. By
analyzing the amino acid sequence of Rubisco large subunit,
we selected two peptide fragments (rubiscolin-5 and rubisco-
lin-6) which could be released by enzymatic digestion and
express a⁄nities to opioid receptors. In the present study
we isolated them from intestinal enzymatic digests of Rubis-
co or synthetic intermediary peptide. The yield of rubiscolin-
5 is quite high in the digests of both spinach Rubisco and
synthetic fragment, and it might have some physiological
signi¢cance. Although we could not detect rubiscolin-6 in
the pepsin-LAP digest of spinach Rubisco, it could be re-
leased by the same enzyme from a synthetic intermediary
peptide. We cannot rule out the possibility that rubiscolin-6
be released under in vivo condition. This is the ¢rst example
that bioactive peptides were obtained from Rubisco by in-
testinal enzymatic digestion.
Considering the structure of rubiscolin-5 and -6 which share
the common sequence YPL- therein, our results further fa-
vored our hypothesis that sequence YPX comprising aliphatic
X besides aromatic X can also induce opioid activity.
Previously, we isolated a N opioid peptide gluten exorphin
A5 (GYYPT) from digest of wheat gluten [4]. Its IC50 in
MVD assay was 60 WM, being weaker than our newly isolated
rubiscolin-5 and -6. The selectivity of gluten exorphin A5
toward N against W in terms of IC50 ratio in GPI and MVD
assays was 16.7, while those of rubiscolin-5 and -6 were 21.8
and 30.7, respectively. Similarly, W/N selectivity in receptor
binding assays was 467 for gluten exorphin A5, whereas those
of rubiscolin-5 and -6 were s 500 and s 2000, respectively.
Gluten exorphin B5 (YGGWL), another N opioid peptide de-
rived from wheat gluten, was a very potent N agonist
(IC50 = 0.017 WM in MVD assay); however, its selectivity W/
N (2.9 in GPI/MVD, 9.0 in receptor binding) [4] was less than
those of rubiscolin-5 and rubiscolin-6. Thus, to our best
knowledge, rubiscolins are the most selective N opioid peptides
derived from food protein, so far reported.
When applied i.c.v., rubiscolins showed an antinociceptive
e¡ect that is typical for opioid. Interestingly, both peptides
induced antinociception after oral administration, which never
occurs for endogenous opioid peptides. The reason might be
interpreted by the concept that endogenous opioid peptides as
well as some exogenous opioid peptides such as gluten exor-
phin B5 (which has the similar structure with enkephalins) are
rather vulnerable to endogenous peptidase, while rubiscolins
would be more stable due to the sequence YP- in their mol-
ecules. Although gluten exorphin A5 also possesses the se-
quence YP-, it failed in inducing antinociception at a dose
of 300 mg/kg after oral administration [27]. In contrast, how-
ever, signi¢cant antinociception was induced by rubiscolin-5
at the same dose, and rubiscolin-6 induced antinociception at
even a lower dose of 100 mg/kg. This result is consistent with
the ¢nding that rubiscolin-5 and -6 are more potent than
gluten exorphin A5.
It is worthy to note that food protein derived opioid pep-
tides of animal origin such as hemorphin and L-casomorphin
are mainly W selective, while those of plant origin such as
gluten exorphin A and B, as well as our newly isolated rubis-
colin are mainly N selective. Despite of their biological signi¢-
cance being unclear, rubiscolins might appear on the earth
much earlier than did animal opioid receptors and endoge-
nous opioid peptides. In this context, their e¡ect on plants
themselves and insects may pose another intriguing question
for us.
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